Skip to content
Anirban Maitra· @Aiims1742 · X·· 2026-04-21Score60

daraxonrasib

Reading

KRAS / RAS targeting: from platform to Phase 3

The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.

The floor rewrote the question from “how long can G12C monotherapy last” to “who first makes first-line pancreatic cancer a standard.” daraxonrasib’s Phase 3 is still the only RAS-inhibitor overall-survival win.

Body

What a time to be alive when I have to choose between attending Brian Wolpin’s talk on Daraxonrasib + chemo in 1st line #PancreaticCancer OR
@RevMedicines
talk on their preclinical asset RM-055 that overcomes KRAS inhibitor resistance, BOTH at the exact same time!
#AACR26

Heat 117 · 98 likes · 5 replies · 14 reposts

Conference abstracts
LB407NCT05379985NCT06445062matched by 药名 daraxonrasib
Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC)

Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, Joel Randolph Hecht, Shubham Pant, Shiraj Sen, E. Gabriela Chiorean, W. Clay Gustafson, Hina Patel, Vidya Seshadri, Yan Zheng, Davendra Sohal

Read the abstract →

Source: Anirban Maitra · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org